Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dendreon Corporation (DNDN) Earnings: An Early Look

Earnings season is now starting to wind down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Dendreon Corporation (NASDAQ:DNDN) is about to release its quarterly earnings report. The key to making smart investment decisions with stocks releasing their quarter reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.

Dendreon Corporation (NASDAQ:DNDN)Dendreon has been waiting a long time for its Provenge treatment for prostate cancer to take off, but success has been slow in coming for the small biotech. Is this quarter finally going to give Dendreon the breakout it’s been looking for? Let’s take an early look at what’s been happening with Dendreon over the past quarter and what we’re likely to see in its quarterly report on Monday.

Stats on Dendreon

Analyst EPS Estimate ($0.56)
Year-Ago EPS $0.26
Revenue Estimate $82.9 million
Change From Year-Ago Revenue 7.7%
Earnings Beats in Past 4 Quarters 1

Source: Yahoo! Finance.

Will Dendreon cure its ills this quarter?
Analysts haven’t budged on their estimates for Dendreon, but they aren’t terribly optimistic about its future prospects. With losses projected throughout 2013, it’s unclear why shareholders remain excited about the stock. Yet a share-price advance of more than 30% suggests hope for better news in the future.

Dendreon has given investors an up-and-down ride over its history, as early expectations for Provenge turned out to be overly optimistic. In fact, on several occasions last year, Provenge actually saw sales fall sequentially from quarter to quarter. This quarter’s estimate is for modest growth, but at nothing like the pace investors had hoped for when Provenge got FDA approval.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.